INTELLIGENT-FINGERPRINTI
25.10.2021 09:21:54 CEST | Business Wire | Press release
Intelligent Fingerprinting has announced that its saliva-based COVID-19 test now carries CE marking and is available for sale. The new VSS-GP COVID-19 Saliva Test uses a simple swab to collect saliva from just inside the cheek, providing a much easier alternative to current throat and nose tests that can cause gagging, sneezing or distress during sample collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005324/en/
Easier, more comfortable COVID-19 testing
Intelligent Fingerprinting’s reliable and easy-to-use saliva-based lateral flow test supports frequent COVID-19 testing for applications including schools, workplaces, care homes, healthcare, airports, sports events, concerts and prisons.
Keeping plastic usage to a minimum
The Intelligent Fingerprinting COVID-19 test strip uses minimal plastic. It has none of the plastic housing usually associated with lateral flow tests, helping to significantly reduce its environmental impact. The test strip is around 95% lighter than traditional lateral flow devices, reducing the environmental impact of packaging and transportation.
Intelligent Fingerprinting’s Executive Chairman, Philip Hand : “Regular COVID-19 testing continues to be part of our everyday lives, so it’s essential that we make the whole process as simple and comfortable as possible. Our saliva-based test directly addresses this challenge, combining much simpler sample collection with high levels of accuracy. I’m delighted that our test is now CE marked, and we anticipate strong demand from markets around the world.”
How it works
A swab is used to collect the saliva sample from the inside of the lower cheek, which is then mixed with a reagent buffer that has been pre-added to the collection tube in order to release the virus into the solution. The screening test is performed by inserting the tip of the test strip into the sample, providing a positive or negative result at 20 minutes. No instrumentation is required. The test uses gold immunonanoparticle technology to enable the visual detection of bound antigen via a control line and a red line on the test strip when a saliva sample is positive for the SARS-CoV-2 antigen.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
Adtran to showcase industry-leading open optical networking for the AI era at OFC 202612.3.2026 14:00:00 CET | Press release
News summary: Adtran will show how intelligent optical networks can scale infrastructure while controlling power, complexity and security risks Highlights include LiteWave800™, an ultra‑low‑power 800G pluggable transceiver, which sets a new 1pJ/bit benchmark for intra‑data center connectivity Adtran will participate in OIF multi‑vendor interoperability demos and present European‑led innovation through advanced research projects Adtran today announced that it will showcase its latest optical innovations at OFC 2026, taking place from March 15 to 19 in Los Angeles. The company will outline how intelligent, secure and power‑efficient optical networks are shaping the next phase of AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311958018/en/ Adtran’s optical networking technology is helping build the foundation for the AI era. At Adtran’s booth (1001), visitors can explore solutions spanning ultra‑low‑power
Wellesley Hills Financial Goes Global: New London and New York Hubs Signal Aggressive Expansion into Transatlantic Fintech M&A12.3.2026 13:00:00 CET | Press release
With the addition of industry veterans Barry Davis and Bill Shraga, WHF strengthens its cross-border capabilities and scales its specialized Merchant Portfolios platform to a national level. Wellesley Hills Financial (“WHF”), a premier fintech and payments-focused investment bank spanning the lower to upper middle market, today announced a series of senior appointments and geographic expansions that further scale its global advisory platform and deepens its capabilities across the payments and fintech ecosystems. The firm has appointed Barry Davis as Executive Advisor, based in London, added Managing Director Bill Shraga in New York, and expanded its payments consulting subsidiary, Merchant Portfolios (“MP”), with the addition of EVPs Lance McCord in North Carolina and Nolan Pittman in Arizona. Strengthening Transatlantic Connectivity Barry Davis joins WHF as the firm’s first London-based Executive Advisor, marking a significant milestone in WHF’s international expansion. His appointme
Prodalim Strengthens its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in Botanical Extracts Based in Brazil12.3.2026 11:45:00 CET | Press release
The acquisition positions Prodalim to deepen its fast-growing functional beverage solutions offering, accelerate its expansion into the US functional ingredients market, and broaden its presence across emerging markets Prodalim, a global leader in juice and specialty ingredients solutions, announced today the acquisition of Sylvestre, a leading Brazilian producer of botanicals and functional extracts addressing the nutraceutical market. Sylvestre’s existing owners and management team will remain with the company and support its integration into Prodalim’s platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312584318/en/ Founded in 1992 in Brazil, Sylvestre is a trusted supplier of high-quality natural ingredients, specializing in botanical extracts, fruit powders, superfruits, teas, and unique functional plant-based solutions sourced from the rich and diverse Brazilian flora. With a portfolio of more than 200 natural
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 202612.3.2026 11:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on March 18, 2026, at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom